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Fluorescence immunohistochemical detection of hypoxic cells in spheroids
and tumours
J.A. Raleigh, G.G. Miller, A.J. Franko, C.J. Koch, A.F. Fuciarelli & D.A. Kelly
Radiobiology, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, T6G IZ2, Canada.
Summary Polyclonal antibodies have been raised in rabbits to a haemocyanin adduct of a reductively-
activated, fluorinated analogue of misonidazole. Fluorescence immunohistochemical studies show that the
polyclonal antibodies bind to spheroid sections and tumour sections in patterns similar to those revealed by
autoradiographic studies with a tritium-labelled derivative of the fluorinated misonidazole analogue.
The metabolic binding of nitroaromatic compounds to
hypoxic cells (McCalla et al., 1970; Varghese et al., 1976;
Miller et al., 1982) has been tested in both experimental
(Chapman et al., 1981; Garrecht and Chapman, 1983;
Franko, 1985; Hirst et al., 1985) and human tumours
(Urtasun et al., 1986a, b) as an indicator of the presence of
tumour hypoxia. It is possible that this information will be
of use in tumour treatment design, whether it be in the
application of radiosensitising strategies (Chapman, 1984;
Franko, 1986) or of hypoxia-activated chemotherapeutic
agents (Kennedy et al., 1980). A number of approaches to
the detection of 2-nitroimidazole adducts bound to macro-
molecules in hypoxic cells are under investigation including
y-ray emission tomography (Jette et al., 1983; Rasey et al.,
1985b; Wiebe et al., 1984), autoradiography (Chapman et al.,
1981; Urtasun et al., 1986a, b) and 19F magnetic resonance
spectroscopy (MRS) (Raleigh et al., 1986). To our knowledge
there are no reports of the use of fluorescence immuno-
histochemistry on tissue sections for this purpose. Although
physically invasive, the technique would not require the use
of radioactive tracers and ultimately might be applied to
biopsy material. Initially, we chose to develop a histochemical
assay based upon the hexafluorinated 2-nitroimidazole,
CCI-103F (I), which is presently under investigation in
connection with '9F MRS studies (Raleigh et al., 1986).
Polyclonal antibodies have been raised in rabbits to the
protein adduct of reductively-activated CCI-103F and shown
in fluorescence immunohistochemical studies to bind to
spheroid and tumour sections in patterns similar to those




The synthesis of 1-(2-hydroxy-3-hexafluoroisopropoxy-
propyl)-2-nitroimidazole (CCI-103F, (I)) has been described
previously (Raleigh et al., 1986). Its tritium-labelled analogue
([3H]-CCI-103F) was synthesized in a manner analogous to
that described for misonidazole (Born & Smith, 1983). The
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specific activity of [3H]-CCI-103F was 9.25 MBqmg- 1.
Bovine serum albumin Fraction V (BSA), Limulus
polyphemus haemolymph Type VIII (haemocyanin), poly-
oxethylenesorbitan monolaurate (Tween 20) and p-nitro-
phenyl phosphate (Sigma 104 phosphatase substrate) were
purchased from the Sigma Chemical Company; polyvinyl
chloride 96-well microtitre plates were from Dynatech
Laboratories Inc.; foetal calf serum, goat serum and
Freund's adjuvants were from Gibco Laboratories Inc.; goat
anti-rabbit alkaline phosphatase conjugate was from Miles
Laboratories Inc., and Spectropor dia4ysis membranes
(molecular weight cut-off 6,000-8,000) were from Spectrum
Medical Ind. Inc. DEAE Sepharose CL-6B was obtained
from Pharmacia Inc. All other chemicals were reagent grade
and used as received from local suppliers.
Immunogens
For the purpose of raising antibodies, CCI-103F was
reductively bound to haemocyanin by an adaptation of a
radiation chemical reduction method (Whillans & Whitmore,
1981). CCI-103F (8.4mg) was dissolved in 25ml of
0.1 mol. dm -3 aqueous isopropanol (pH 3.0). Haemocyanin
(25mg) was added to the solution which was then deaerated
in a gassing manifold in a manner similar to that described
below for the deoxygenation of multicellular spheroids. The
deaerated solution was irradiated to a dose of 104Gy at a
dose-rate of 28 Gymin-1. This dose was sufficient to
completely reduce the nitro group in CCI-103F as measured
by ultraviolet spectroscopy at 320nm. The irradiated
solution was placed in a dialysis membrane and dialysed
extensively against 0.14mol.dm-3 NaCl, 1.5mmol.dm-3
KH2PO4, 8mmol.dm -3 Na2HPO4, 3mmol.dm -3 KCI,
pH 7.4 (PBS) to remove unbound CCI-103F. The dialysed
solution was concentrated in vacuo to 7.0ml in a rotary
evaporator (40°C). The haemocyanin had clumped during
this procedure and the suspension was sonicated before
being divided in 1.0ml aliquots and stored at -17°C. A
bovine serum albumin (BSA) conjugate with reductively
activated CCI-103F was also prepared for use in the
characterisation of antisera to CCI-103F by enzyme-linked
immunosorbent assay (ELISA). In a separate experiment on
a smaller scale with tritium-labelled CCI-103F, it was deter-
mined that - 15 molecules of CCI-103F were bound to each
molecule of BSA. It is assumed that a similar binding
efficiency occurred with haemocyanin. However, the
tendency of haemocyanin to clump during the dialysis step
prevented a direct assessment of binding efficiency in a small
scale reaction involving radioactive CCI-103F.
Immunisation and treatment ofantisera
Two Flemish Giant x Lop-ear rabbits (one male, one female)
were injected with the haemocyanin-CCI-103F conjugate.
Prior to the initial immunisation, 20ml of blood were
Br. J. Cancer (1987), 56, 395-400 (D The Macmillan Press Ltd., 1987396 J.A. RALEIGH et al.
collected from the ear vein of each rabbit. These preimmune
serum samples were used as control sera in subsequent
assays. Each rabbit received a total of 0.4ml of the antigen
(-3.6mg proteinml-1) emulsified with an equal volume of
Freund's complete adjuvant injected at multiple subscapular
sites. Similar booster injections emulsified in Freund's incom-
plete adjuvant were administered by the same route on days
21, 42 and 63. Sera (1Oml) were collected on days 21, 42 and
63. Immediately following collection, the blood was allowed
to clot, the serum was drawn off and centrifuged twice.
Aliquots of 0.5 ml were stored at - 17°C.
ELISA methodology
The sera were characterised by ELISA methods described
previously including reagent dilution assay and competitive
inhibition assay (Fuciarelli et al., 1985). The extent of color
development from the alkaline phosphatase substrate (Sigma
104 phosphatase substrate) was recorded using an EL 309
Microplate Autoreader at 410 nm.
Spheroid culture
Spheroids of EMT6/Ed tumour cells were cultured following
procedures that have been published (Franko, 1985). Briefly,
spheroids were initiated in non-tissue culture dishes (Lab
Tek), to which the cells do not adhere. After an initial
aggregation into clumps of 10-50 cells, the spheroids grew
by cell proliferation. When they reached a diameter of 0.4-
0.6mm, they were transferred to 250ml spinner flasks (O.H.
Johns). After a lag phase of 2-3 days, the spheroids grew
0.1 mmday- . On the fourth day in spinner flasks,
spheroids of 0.8+0.05mm were selected and returned to the
flasks at a density of one spheroid per 2ml medium. The
growth medium, Waymouth's with 12% foetal calf serum
(Gibco) was replenished daily. The spheroids were used on
the eighth day in spinner flasks, when their diameters were
1.2+0.1 mm. The flasks were flushed continuously with
humidified air - 5% CO2 at 0.1 minm for 2 days prior to
use of the spheroids.
Incubation of spheroids with misonidazole and CCI-103F
In an experiment designed to compare the binding of
misonidazole and CCI-103F, labelling of the spheroids with
[3H]-misonidazole (2.89TBqmol - 1, 14.4 MBqmg-1) or [3H]-
CCI-103F (3.15TBqmol-, 9.25MBqmg-1) was performed
in the original growth flasks. For incubation in air, the drug
was added in 0.2ml medium to a final concentration of
0.10mmol. dm-3. For incubation at low oxygen the flasks
were flushed with N2 - 5% CO2 for 1.5 h before the drug
was added. This procedure results in an oxygen concen-
tration equal to that in medium equilibrated with N2 - 5%
CO2 -0.13% 02 (Franko et al., 1984). Three hours after the
drugs were added, the spheroids were rinsed several times
with PBS and processed for autoradiography.
For incubation with non-radioactive CCI-103F in the
fluorescence immunohistochemical studies, the spheroids
were transferred with 20mmol . dm-3 HEPES buffer (Gibco)
to glass petri dishes containing 5.5 ml of Waymouth's
medium. A separate growth flask was used for each of the
two incubation conditions. The dishes were placed inside
aluminium chambers fabricated with a removable base which
forms a leakproof seal (via an 0-ring) upon reassembly. The
chambers were degassed to an oxygen content (0.0005%)
which is much lower than that achieved in spinner flasks.
The chambers were kept at 0°C during the degassing, then
placed in a 37"C environmental chamber on a reciprocating
table (1.1 Hz, 3cm travel) for 3.5h. The dishes warmed to
37"C in 30min. After incubation, the spheroids were rinsed
several times in PBS and processed for histochemistry.
Incubation in air under these conditions might alter the
oxygen supply to the spheroids somewhat from that present
in spinner flasks. However, this was not deemed an
important factor in the qualitative comparison reported here
for the results obtained with autoradiography and fluor-
escence immunohistochemistry. Ultimately, the chamber
system (Franko et al., to be published) will facilitate quan-
titative comparisons of measurements of drug binding by the
two techniques under carefully controlled conditions.
Autoradiography andgrain scoring
The spheroids were dehydrated, embedded in wax and
sectioned at 4,pm. The slides were dipped in NTB-2 Nuclear
Track Emulsion (Kodak) and exposed for 5 days. The
emulsion was developed, fixed and dried, then the sections
were stained with haematoxylin and eosin. The sections
which passed through the centres of the spheroids were
determined and these were used for scoring the grain density.
An ocular grid with 10,pm squares at an overall magnifi-
cation of 1000 x was positioned along a spheroid radius
perpendicular to the direction of sectioning (to minimise the
effects of distortion resulting from compression during
sectioning) and grains were recorded as a function of
distance from the spheroid surface. The grain densities along
13 to 18 radii from nine different spheroids were averaged
for each incubation condition.
Labelling of Walker 256 tumours with CCI-103F
Walker 256 tumours were initiated by subcutaneous implan-
tation of frozen stock in the flanks of Sprague Dawley rats.
Ten days after implantation, a rat with two tumours 1.5 to
2.0cm in diameter was injected i.p. with 20mg of CCI-103F
in 20ml of sterile saline, giving a whole body concentration
of 200,pM. The tumours were excised 24h after the injection
and fixed for 2 h in -20°C ethanol, then embedded in wax
on the same day. Sections were obtained at 4 um and
processed for immunohistochemistry following the
procedures that were used for the spheroid sections.
Histochemistry
EMT6/Ed spheroids were fixed in - 20°C ethanol (Sainte-
Marie, 1962) and embedded in paraffin. Sections (2-4pm)
were deparaffinised, hydrated through an alcohol series and
rinsed in PBS, pH 7.2, prior to overnight incubation at 4°C
in rabbit anti-CCI-103F serum diluted 1:50 in the same
buffer. Following extensive rinsing in PBS, the sections were
incubated for one hour at 37°C in rhodamine-conjugated,
goat-antirabbit IgG (Cappel, Cooper Biomedical). Negative
controls included substitution of the primary antibody with
non-immune rabbit serum diluted 1:50 in PBS, or of the
standard staining procedure of sections of multicellular
spheroids which had not previously been incubated with
CCI-103F. The tissue sections were rinsed and coverslipped
with PBS-glycerol, 9:1 and observed with a Leitz Laborlux
12 microscope fitted with an HBO 5OW mercury burner and
IVFI epifluorescence condenser. Rhodamine was visualised
with an interference green filter combination BP 530-560 and
RKP 580 beam splitter. Fluorescence microphotographs were
made using equal exposure times for each experimental




A sample of antiserum from one of the rabbits was screened
using the BSA-CCI-103F conjugate to coat the wells of the
microtitre plates. A 1000-fold dilution of the conjugate
containing 3.6mgml- 1 BSA-CCI-103F provided optimal
absorption (Figure 1). Reducing the concentration of the
BSA-CCI-103F conjugate in the coating buffer below
0.4pgml- 1 significantly reduced the maximum ELISA value.
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Figure 1 Reagent dilution assay for anti-haemocyanin-CCI-
103F antiserum. Antiserum containing anti-haemocyanin-CCI-
103F antibodies was screened with microtitre plates in which the
wells were coated with BSA-CCI-103F conjugate in an ELISA.
(Dilution of conjugate in coating buffer: 10- 2, 10-3, 10 -4 and
10 -5).
specific cross-reactivity with the antiserum which could be
blocked with very low concentrations of BSA test solutions
in the wells of the microtitre plate. The titre of the antiserum
was 10- 5and did not change after repeated immunisation of
the rabbits. A 50% positive response occurred at a 104-fold
dilution of antiserum and competitive inhibition studies were
performed at this dilution.
Specificity of the antiserum
Although the exact nature of the adduct of reductively-
activated CCI-103F with proteins and other cellular
molecules is not known, a series of chemicals was tested for
ability to inhibit the binding of the antiserum to BSA-CCI-
103F conjugate which was immobilised by adsorption to the
surface of the wells in the microtitre plate. Competition for
the anti-haemocyanin-CCI-103F antibodies was most
efficient with CCI-103F itself (Figure 2). The fact that none
of imidazole, 2-nitroimidazole, misonidazole, nor D,L-
histidine showed a strong interaction with the antiserum
indicates that the fluorinated side-chain of CCI-103F is the
major antigenic determinant. The weak inhibitory effect of
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Figure 2 Competitive inhibition curves for anti-haemocyanin-
CCI-103F antiserum. Dilutions of the various compounds were
preincubated with antiserum at a final dilution of 10t then
added to microtitre wells coated with 3.6mgml-1 of BSA-CCI-
103F conjugate for competitive ELISA. CCI-103F (0), 2-nitro-
imidazole (A), D,L-histidine (A), hexafluoropropanol (D),
misonidazole (-).
more of the side chain than the terminal hexafluoro-
isopropoxy group in CCI-103F.
Fluorescence immunohistochemistry
Sections of spheroids which had been incubated with CCI-
103F in the absence of oxygen showed a uniform fluor-
escence intensity from the surface of the spheroid inward to
the edge of the necrotic centre (Figure 3a). For spheroids
incubated in air-saturated medium containing CCI-103F, the
fluorescence intensity which increases over the first 100-
150,pm of the periphery, achieved maximum intensity near
the inner edge of the rim of viable cells (Figure 3b). These
patterns are similar to the patterns of binding revealed in
autoradiographic studies of adducts formed between cellular
molecules and [14C]- or [3H]-misonidazole (Franko, 1985;
Raleigh et al., 1985) or with [3H]-CCI-103F (see below). This
is consistent with an ability of the fluorescence immuno-
histochemical assay to discriminate between aerated and
hypoxic cells. The fraction of cells in EMT6/Ed spheroids
which is radiobiologically hypoxic has been shown to be
-20% (Franko & Koch, 1983).
The fluorescence immunohistochemical assay is qualitative
at this stage, but it is possible to define its ability to
discriminate between oxygenated and hypoxic cells by
reference to autoradiographic studies of [3H]-CCI-103F
bound to spheroids labelled in air or in the absence of
oxygen. The patterns of fluorescence in the spheroid sections
(Figure 3) are comparable to the distribution of grain counts
in EMT6/Ed spheroids grown under similar conditions. For
example, a four-fold increase in [3H]-CCI-103F binding
occurs in going from the well-aerated outer cells to the
hypoxic cells adjacent to the necrotic centre of spheroids
labelled in air with [3H]-CCI-103F (Figure 4, dashed line). In
the case of spheroids labelled in the absence of oxygen,
uniform grain counts are observed from the periphery
inward to the necrotic zone (Figure 4, solid line). It can be
seen (Figure 4) that spheroids labelled in air with [3H]-
misonidazole show a greater difference in grain density
between aerobic and hypoxic cells than is the case for
labelling with [3H]-CCI-103F. This is because the more
hydrophobic CCI-103F (Raleigh et al., 1986) binds more
avidly to aerated cells than does misonidazole. Nevertheless,
CCI-103F binding can discriminate between these two types
of cells almost as well as can misonidazole.
Figure 3c is a haematoxylin-eosin-stained section ofWalker
256 carcinoma labelled in vivo with CCI-103F as described in
Materials and methods. In the centre of the field a zone of
relatively healthy cells is evident which is bounded on three
sides by necrotic cells and cellular debris. An adjacent tissue
section, immunohistochemically stained for the hypoxic
marker (Figure 3d) reveals positive staining of the zone of
necrotic cells and several layers of healthy cells adjacent to
the necrotic regions. The fluorescent labelling of areas
bordering necrotic regions was observed consistently
throughout the tumour tissue sections.
Discussion
Recent success in the use of non-invasive 19F magnetic
resonance spectroscopy to detect the binding of fluorinated
2-nitroimidazoles to tumour hypoxia in vivo (Raleigh et al.,
1986; and in preparation) has led to an interest in developing
an ancillary, non-radioactive histochemical assay for
hypoxia. It was known that the side chain of a substituted 2-
nitroimidazole is efficiently bound to hypoxic cells (Raleigh
et al., 1985; Rasey et al., 1985a) and the hexafluoroiso-
propoxy group in CCI-103F seemed a likely target for the
development of a fluorescence immunohistochemical assay.
Considerable progress has been made in studies of the
chemistry of the reductive activation of 2-nitroimidazoles
(Whillans & Whitmore, 1981; Varghese, 1983; Raleigh &
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Figure3 (a) Indirect immunofluorescence photomicrograph ofa section ofan EMT6/Ed spheroid which was labelled with CCI-103F
in nitrogen. The outer surface of the spheroid is to the left. The outer rim of viable cells (approximately one-half of the field) is
strongly labelled; indicating reductive binding of CCI-103F to macromolecules in the hypoxic cells. The necrotic cells and debris at
the centre of the spheroid remain unlabelled (x 500). (b) Indirect immunofluorescence photomicrograph of a section of an
EMT6/Ed spheroid which was labelled with CCI-103F in air. The presence of oxygen at the spheroid periphery inhibits
binding of the compound. The innermost viable cells at the edge of the necrotic centre are known to be hypoxic under the
conditions of incubation with CCI-103F (normal growth conditions), and these are the cells which are strongly labelled. Cells and
debris in the necrotic interior remain unlabelled ( x 500). (c) Haematoxylin-eosin stained section of Walker 256 carcinoma. Note
central zone of relatively healthy cells flanked by a region of necrotic cells and connective tissue (x 500). (d) Adjacent tissue
section of Walker 256 carcinoma immunohistochemically stained for the presence of adducts of CCI-103F. The cells of normal
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Figure 4 Grain density in autroradiograms of EMT6/Ed
spheroids labelled with [3H]-misonidazole or [3H]-CCF-103F in
normal growth conditions (air) or in the absence of oxygen (N2).
Points are the means of counts along 20 radii from ten
spheroids. Error bars are 95% confidence limits. Spheroid
diameters were 1 .1 to 1.3 mm.
Liu, 1984; McClelland et al., 1984, 1985). In vitro studies
(Raleigh et al., 1985; Rasey et al., 1985a) appear to confirm
the idea that the binding agent is a molecular product
incorporating both ring and side chain of reduc-
tively-activated 2-nitroimidazoles. At present, the evidence
favours an hydroxylamine derivative (II) as the binding
agent (Varghese, 1983; McClelland et al., 1984, 1985). The
hydroxylamine intermediate is stabilised to hydrolytic de-
composition at pH values less than 4 (McClelland et al.,
1984). This, combined with the knowledge that proteins are
major sites of binding in hypoxic cells (Miller et al., 1982;
Smith, 1984), led to preparation of an immunogen formed
by the radiation chemical reduction of CCI-103F at pH3 in
the presence of a suitable protein such as haemocyanin. The
efficient binding of CCI-103F under these conditions, in a
way in which the side-chain is preserved, is consistent with
the binding of an hydroxylamine intermediate to protein
sulphhydryl and amino groups. The situation is analogous to
that proposed for the binding of reductively-activated 2-
nitroimidazoles to glutathione (Varghese, 1983; Smith &
Born, 1984). The successful development of a fluorescence
immunohistochemical detection for CCI-103F opens the
possibility that the present approach may be useful in raising
antibodies to 2-nitroimidazoles with a variety of side-chains.
The hydrolytic instability of the hydroxylamine inter-
mediate at neutral pH (McClelland et al., 1984) may account
for the limited diffusion of the binding agent away from the
hypoxic cells (Franko et al., 1982; Chapman et al., 1983;
Franko & Koch, 1984). This is an essential property of
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nitroaromatic compounds. The close correspondence of
binding patterns of [3H]-misonidazole and [3H]-CCI-103F in
spheroids (Figure 4) indicates that the binding intermediate
formed from each has similar diffusion properties, even
though the side-chain differs markedly in polarity. Never-
theless, in some cases, the side chain does affect the efficiency
of reductive binding of 2-nitroimidazoles to both cells
(Chapman et al., 1983) and nucleic acids (Silver et al., 1986).
These distinctions may ultimately be important to hypoxia
marker development.
The fluorescent labelling pattern observed in oxygenated
and hypoxic spheroids is consistent with the pattern
previously demonstrated by autoradiography (Figure 4 and
Franko et al., 1982, 1984; Franko, 1985, 1986). The labelling
pattern of cells adjacent to necrotic regions in the Walker
256 carcinoma is consistent with the hypoxic fraction of 7%
reported for this tumour (Clement et al., 1978), and is
encouraging regarding the utility of the immunohisto-
chemical approach to detect hypoxia in vivo. The amount of
CCI-103F used to label the tumour in vivo produced no
obvious long term toxicity although a transient depressive
effect was noted. Lower whole body concentrations over
longer exposure times, which was achieved by repeated
injections, also produced binding of CCI-103F to hypoxic
cells in tumours but no obvious long term toxicity (Raleigh
et al., 1986). A much more detailed study of CCI-103F
toxicity is required, however, before its clinical application is
considered.
The long range goal of our research is to develop a
physically non-invasive method of measuring hypoxia in
human tumours. We believe that 19F MRS offers some
potential in this regard (Raleigh et al., 1986; and in
preparation) and are studying a selection of fluorinated
2-nitroimidazoles as potential markers. The availability of
a correlative assay during the development stages of the
19F MRS approach is viewed as essential. To date we have
relied on quantitative autoradiography and scintillation
counting of excised tumours labelled with tritiated versions
of the fluorinated compounds as a means of establishing the
19F MRS technique. The fluorescence immunohistochemical
technique would have the important advantage of eliminating
the need for using radioactive compounds if the fluorescence
intensity could be quantified. Efforts to do so are presently
underway.
It is conceivable that in the absence of a physically non-
invasive assay of tumour hypoxia such as 19F MRS, a
fluorescence immunohistochemical technique applied to
biopsy material could become an acceptable way of
establishing the degree of initial tumour hypoxia or, with
multiple fluorescence agents, the course of reoxygenation
during radiation therapy. In fact, even with a non-invasive
technique like 19F MRS which can only provide an inte-
grated signal of total drug binding to a tumour, it may be
necessary to establish by means of an histochemical examin-
ation of a biopsy sample what the initial distribution of
hypoxia is in the tumour. There would be a real advantage
to using a non-radioactive marker for this step. It is also
clear that a fluorescence immunohistochemical assay based
on 2-nitroimidazoles which are presently in clinical use is
desirable and attempts to develop such an assay have been
undertaken.
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